integrase inhibitor


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia, Wikipedia.

integrase inhibitor

Any agent that prevents the human immunodeficiency virus from inserting its viral DNA into host cell chromosomes.
See also: inhibitor
References in periodicals archive ?
Of the 229 people studied, 108 (47%) began therapy with a PI, 81 (35%) with an NNRTI, and 40 (18%) with the integrase inhibitor Isentress.
Retroviral integrase inhibitors year 2000: update and perspectives.
The Tivicay clinical development programme was comprehensive in its breadth, including people living with HIV who were new to treatment (naive), as well as those who had already been treated with other HIV medicines (experienced) and those who were infected with a virus that had developed resistance to previously available integrase inhibitors.
Studies have found that integrase inhibitors can suppress virus that is resistant to some of these other ARVs, including those in a class called nucleoside/nucleotide reverse transcriptase inhibitors.
About Triumeq Triumeq (dolutegravir/abacavir/lamivudine) is not currently approved in any country and is an investigational once-daily single tablet dolutegravir based regimen, containing the integrase inhibitor dolutegravir which was approved by the EMA in January 2014 under the brand name Tivicay[sup.
dolutegravir) is an integrase inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 in adults and children aged 12 years and older weighing at least 40 kg.
New data showing efficacy in previously untreated patients with HIV have moved the integrase inhibitor raltegravir into the starting lineup, Dr.
A research article published in the journal The Lancet reveals that the scientists found that an HIV integrase inhibitor called Raltegravir is overall as effective as widely used efavirenz, a reverse transcriptase inhibitor.
Two randomized trials that signed up people with well-controlled HIV while taking Kaletra (lopinavir/ritonavir) found that switching those protease inhibitors (PIs) to the integrase inhibitor Isentress (raltegravir) was not as effective as staying with Kaletra.
HIV integrase was recognised as a possible target early in the HIV epidemic [1], but development of an effective integrase inhibitor was haltingly slow due to issues of potency, protein binding and toxicity.
As per the arrangement, Ranbaxy will extend its existing relationship with Gilead for anti-retrovirals and have the rights to manufacture and market generic equivalents of new products, Elvitegravir, an investigational integrase inhibitor, Cobicistat, an investigational antiretroviral boosting agent and Quad, which combines four Gilead HIV medicines in a once-daily, single-tablet regimen.
Merck reported that its experimental integrase inhibitor MK-0518 reduced HIV viral load 98%, in a 10-day monotherapy trial in 28 treatment-naive volunteers.